GoAI
Get started
Arts Optical International Holdings Limited logo

Arts Optical International Holdings Limited

1120.HK

HKSEHealthcareMedical - Instruments & Supplies

Open in GoAI

Latest quote

HK$0.605

+HK$0.005 · +0.83%

Aug 10, 4:08 PM HKT

1120.HK company overview

Historical prices · Market data may be delayed.

Company profile

Company website

Arts Optical International Holdings Limited operates as an investment holding company with primary involvement in the design, production, and global distribution of eyewear. Its diverse product offerings include prescription spectacle frames, sunglasses, and optical lenses. The firm caters to markets across Europe, the United States, Asia, and various other international territories. These products are marketed and sold under a portfolio of brands such as CEO-V, Dakota Smith, CV, MINIBOXX, PAULO PILIPE, Laura Ashley, RetroCraft, and AustSports. Additionally, the company engages in property holding activities. Founded in 1973, Arts Optical is headquartered in Kwun Tong, Hong Kong.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
HK
CEO
Yat Shan Ng
Listed since
Nov 8, 1996
Employees
3,500

Market position

52-week range

Current HK$0.605

Open
HK$0.605
Previous close
HK$0.60
Volume
8K
0.27× average
Average volume
29.89K
Average daily volume
Market cap
233.69M HKD
Beta
0.02
Market reference 1
50-day average
HK$0.7284
-16.94% below average
200-day average
HK$0.8508
-28.89% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
591.7M HKD
P/E (TTM)
11.29×
P/B (TTM)
0.41×
P/S (TTM)
0.18×
EV / EBITDA
5.02×
Earnings yield
5.64%
Free cash flow yield
-49.37%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
31.39%
Operating margin
3.94%
Net margin
1.55%
Return on equity
3.63%
Return on assets
1.29%
Return on invested capital
2.53%

Financial health

Debt / equity
0.63×
Current ratio
1.19×
Altman Z-score
2.39
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends34%22%10%-2%Gross margin, FY2021: 25.96%Gross margin, FY2022: 26.92%Gross margin, FY2023: 31.01%Gross margin, FY2024: 29.36%Gross margin, FY2025: 31.39%Operating margin, FY2021: 2.46%Operating margin, FY2022: 10.75%Operating margin, FY2023: 3.52%Operating margin, FY2024: 1.70%Operating margin, FY2025: 3.94%Net margin, FY2021: 1.80%Net margin, FY2022: 10.03%Net margin, FY2023: 4.29%Net margin, FY2024: 0.89%Net margin, FY2025: 1.55%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 25.96%. Gross margin FY2022 26.92%. Gross margin FY2023 31.01%. Gross margin FY2024 29.36%. Gross margin FY2025 31.39%. Operating margin FY2021 2.46%. Operating margin FY2022 10.75%. Operating margin FY2023 3.52%. Operating margin FY2024 1.70%. Operating margin FY2025 3.94%. Net margin FY2021 1.80%. Net margin FY2022 10.03%. Net margin FY2023 4.29%. Net margin FY2024 0.89%. Net margin FY2025 1.55%.

Income trends

Revenue

1.33B HKD+4.02%

Operating income

52.56M HKD+141.74%

Net income

20.7M HKD+81.30%
Income trends across reported periods1.47B HKD937.14M HKD408.16M HKD−120.83M HKDRevenue, FY2021: 1.15B HKDRevenue, FY2022: 1.14B HKDRevenue, FY2023: 1.2B HKDRevenue, FY2024: 1.28B HKDRevenue, FY2025: 1.33B HKDOperating income, FY2021: 28.38M HKDOperating income, FY2022: 122.99M HKDOperating income, FY2023: 42.07M HKDOperating income, FY2024: 21.74M HKDOperating income, FY2025: 52.56M HKDNet income, FY2021: 20.7M HKDNet income, FY2022: 114.77M HKDNet income, FY2023: 51.32M HKDNet income, FY2024: 11.42M HKDNet income, FY2025: 20.7M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.15B HKD. Revenue FY2022 1.14B HKD. Revenue FY2023 1.2B HKD. Revenue FY2024 1.28B HKD. Revenue FY2025 1.33B HKD. Operating income FY2021 28.38M HKD. Operating income FY2022 122.99M HKD. Operating income FY2023 42.07M HKD. Operating income FY2024 21.74M HKD. Operating income FY2025 52.56M HKD. Net income FY2021 20.7M HKD. Net income FY2022 114.77M HKD. Net income FY2023 51.32M HKD. Net income FY2024 11.42M HKD. Net income FY2025 20.7M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue1.33B HKD1.28B HKD1.2B HKD1.14B HKD1.15B HKD
Cost of goods sold915.19M HKD905.79M HKD825.32M HKD836.1M HKD853.63M HKD
Gross profit418.68M HKD376.48M HKD370.99M HKD308M HKD299.31M HKD
Selling, general, and administrative387.23M HKD369.56M HKD351.84M HKD315.49M HKD284.64M HKD
Operating expenses366.12M HKD354.74M HKD328.92M HKD189.63M HKD276.19M HKD
Interest income225K HKD461K HKD850K HKD430K HKD257K HKD
Interest expense10.79M HKD5.07M HKD685K HKD1.55M HKD1.47M HKD
Depreciation and amortization43.78M HKD26.58M HKD35.02M HKD33.33M HKD20.16M HKD
Operating income52.56M HKD21.74M HKD42.07M HKD122.99M HKD28.38M HKD
Net income20.7M HKD11.42M HKD51.32M HKD114.77M HKD20.7M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
0.02

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.260.160.05-0.05Q2 '21Q4 '21Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25
Q2 2021, reported Jun 30, 2021: actual -0.015, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 0.068, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 29, 2022: actual 0.074, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 29, 2023: actual 0.223, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 29, 2023: actual 0.056, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 27, 2024: actual 0.077, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 29, 2024: actual 0.006, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 27, 2025: actual 0.023, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.59B1.21B829.89M450.6MQ2 '21No estimateQ4 '21No estimateQ3 '22MissQ1 '23MissQ3 '23MissQ1 '24MissQ3 '24No estimateQ1 '25No estimate
Q2 2021, reported Jun 30, 2021: actual 529.07M HKD, estimate —, surprise —, Comparison unavailable. Q4 2021, reported Dec 31, 2021: actual 623.87M HKD, estimate —, surprise —, Comparison unavailable. Q3 2022, reported Aug 29, 2022: actual 580.06M HKD, estimate 1.51B HKD, surprise -61.59%, Miss. Q1 2023, reported Mar 29, 2023: actual 564.05M HKD, estimate 1.51B HKD, surprise -62.65%, Miss. Q3 2023, reported Aug 29, 2023: actual 566.45M HKD, estimate 1.51B HKD, surprise -62.49%, Miss. Q1 2024, reported Mar 27, 2024: actual 629.86M HKD, estimate 1.51B HKD, surprise -58.29%, Miss. Q3 2024, reported Aug 29, 2024: actual 606.39M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 27, 2025: actual 675.88M HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.27

2017 complete year+440.0% since 2013

Corporate action history

Dividend

Ex-dividend Jun 11, 2024

HK$0.05

Annual

Record Jun 12, 2024 · Payment Jun 28, 2024

Dividend

Ex-dividend Jun 12, 2023

HK$0.10

Special

Record Jun 13, 2023 · Payment Jun 30, 2023

Dividend

Ex-dividend Sep 12, 2018

HK$0.05

Annual

Record Sep 13, 2018 · Payment Oct 31, 2018

Dividend

Ex-dividend Sep 28, 2017

HK$0.02

Special

Record Sep 29, 2017 · Payment Oct 17, 2017

Dividend

Ex-dividend May 29, 2017

HK$0.25

Special

Record May 31, 2017 · Payment Jun 15, 2017

Dividend

Ex-dividend Sep 29, 2016

HK$0.038

Semi-Annual

Record Sep 30, 2016 · Payment Oct 17, 2016

1120.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.7

-3.94%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.46

-3.61%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.4

-2.89%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.06

-6.11%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$99.50

-2.83%

Continue in GoAI

Research 1120.HK

research.disclaimer